Year: 2022

Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel

DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis

Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE...

error: Content is protected !!